🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Globus Medical, Inc. GMED R3KPHARMA

Healthcare · Medical Devices · United States
https://www.globusmedical.com
Company Profile ↓
$75.04
+19.51% 1Y
Mkt Cap$8.39B
P/E19.19
P/B2.09
52W High$96.82
52W Low$55.10
Book Value$35.52
EPS (TTM)$3.91

Company Overview

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 16.5% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 16.7% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 19.2, below the sector median of 24.8.

Healthy Margins

Maintains a net profit margin of 17.0%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $2.94B (+16.7% YoY); net profit $537.87M.
  • Trailing 12 Months Year-on-year growth — revenue +5.9%, earnings -26.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 16.7%, profit CAGR 16.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:16.74%
1 Year:5.90%

Compounded Profit Growth

5 Years:16.50%
1 Year:-26.20%

Stock Price Performance

1 Year:+19.51%
6 Months:-14.54%
3 Months:-4.16%
1 Month:-8.88%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 48% of range
$55.10 $96.82
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)31.47 · Neutral
Price Performance
1M-8.88%
3M-4.16%
6M-14.54%
1Y+19.51%
Valuation vs Sector

P/E of 19.19 is below the sector median of 24.83 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 16.7% over 5 years.
  • Profit CAGR of 16.5% over 5 years.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
19.19
Industry PE
24.83
Forward P/E
13.90
PEG Ratio
1.49
Book Value
$35.52
Price to Book
2.09
P/S
3.16
EV/EBITDA
9.37
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
16.74%
Profit 5Y
16.50%
Revenue (YoY)
5.90%
Earnings (YoY)
-26.20%

Profitability & Returns

ROCE
9.99%
ROE
11.81%
ROA
8.74%
Profit Margin
17.03%
Op Margin
24.75%
Gross Margin
68.97%
EPS (Latest Qtr)
$1.10
EPS (TTM)
$3.91

Balance Sheet & Liquidity

Debt/Equity
2.35
Quick Ratio
2.78
Current Ratio
4.62
Debt
$111.91M
Total Assets
$5.49B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
0.61%
Chg in Prom Hold
-0.11%
FII / Inst Holding
92.36%
Chg in FII Hold
0.36%

Financial Snapshot

Enterprise Value
$8.39B
Total Revenue (TTM)
$3.14B
EBITDA
$1.01B
Free Cash Flow
$554.19M
Operating Cash Flow
$910.39M
Shares Outstanding
111.83M
Gross Margin
68.97%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 GMED Globus Medical, Inc. R3KPHARMA 75.04 19.19 $8.39B 0.00% 9.99% 11.81% 16.74% 16.50%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue -------155.81M152.39M151.74M176.03M174.41M173.38M169.24M195.94M182.95M194.54M196.22M211.67M190.58M148.92M216.10M233.44M227.34M251.02M229.72M230.55M263.65M254.15M276.69M291.62M383.64M606.67M629.69M625.71M598.12M745.34M769.05M759.85M789.61M
Gross Profit 101.12M104.06M107.65M107.75M104.76M104.20M112.59M120.21M115.19M114.95M135.18M136.44M135.75M131.39M149.98M141.11M150.55M150.83M162.91M141.71M98.28M159.00M172.59M172.32M187.17M171.17M171.38M195.18M188.65M205.86M215.14M248.25M365.18M369.65M------
Operating Income 37.03M40.67M-42.85M37.92M37.65M-40.31M37.37M35.80M-45.63M42.14M38.30M-37.08M42.87M42.06M-28.45M-25.56M50.01M-54.55M45.88M53.33M46.45M67.78M59.70M56.40M66.21M404.00K8.00M49.62M48.10M97.00M76.11M137.36M150.39M182.43M
Net Income 24.05M26.48M37.60M28.01M25.81M26.23M24.30M28.71M28.67M25.59M24.38M39.54M44.98M35.21M36.75M33.21M38.16M38.31M45.53M25.95M-20.84M44.22M52.96M45.33M41.55M47.21M38.08M54.59M47.43M49.13M57.71M998.00K-7.12M31.76M51.84M75.46M202.85M118.97M124.30M151.57M
Diluted EPS 0.250.280.390.290.270.270.250.300.290.260.250.390.440.350.360.330.380.380.440.25-0.210.440.520.440.400.450.370.530.470.480.570.01-0.050.230.380.541.490.880.901.10
R&D Expense 9.08M9.25M-10.03M10.59M10.27M-10.67M10.71M10.89M-12.69M13.52M15.53M-14.32M15.75M14.51M-15.40M39.45M14.42M-14.92M15.55M15.85M17.41M17.39M18.70M21.08M21.35M29.33M57.27M37.70M35.38M33.06M39.95M38.07M36.51M36.32M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 288.19M331.48M385.99M434.46M474.37M544.75M563.99M635.98M712.97M785.37M789.04M958.10M1.02B1.57B2.52B2.94B
Gross Profit 234.37M262.68M310.80M334.12M363.60M412.42M429.29M485.52M553.56M605.39M571.58M718.88M759.12M1.02B--
Operating Income 87.69M97.36M114.79M101.67M138.36M172.22M154.14M161.84M169.32M171.99M111.43M171.95M227.95M133.14M165.99M479.82M
Net Income 54.46M60.78M73.83M68.61M92.48M112.78M104.34M107.35M156.47M155.21M102.28M149.19M190.17M122.87M102.98M537.87M
Diluted EPS 0.600.670.800.730.971.171.081.101.541.521.011.441.851.070.753.92
R&D Expense 21.31M23.46M27.93M26.87M31.17M36.31M44.53M43.68M55.50M60.07M84.52M97.35M73.02M124.01M163.75M147.25M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --329.39M447.13M566.30M703.55M834.10M927.64M1.08B---1.30B---1.53B---1.68B---1.96B---2.08B5.09B5.25B5.30B
Total Equity 167.75M228.19M282.48M386.50M472.36M585.45M715.32M832.08M967.78M1.03B1.10B1.14B1.19B1.24B1.29B1.34B1.40B1.36B1.34B1.42B1.51B1.56B1.64B1.72B1.74B1.79B1.70B1.76B1.85B4.00B4.18B4.57B
Cash & Equivalents 50.65M111.70M142.67M212.40M89.96M82.27M57.65M66.95M118.82M---139.65M---195.47M-------------784.44M526.16M
Total Liabilities --46.91M60.63M93.94M118.09M118.78M95.56M110.72M---115.15M---129.62M---173.19M---215.88M---229.75M1.09B1.07B729.51M
Current Liabilities --29.27M39.51M67.94M89.41M82.69M79.89M93.07M---96.12M---111.40M---120.79M---140.16M---159.20M392.35M855.91M498.50M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 71.29M76.41M76.52M93.47M79.17M124.01M147.82M159.06M181.64M171.97M198.79M276.27M178.47M243.50M520.64M753.45M
Investing Cash Flow -12.00M-29.99M-30.71M-227.15M-100.00M-153.05M-162.74M-111.28M-193.03M-140.28M-117.32M-375.94M-110.36M302.97M-176.05M-355.01M
Financing Cash Flow 1.77M-14.73M24.02M11.01M12.95M4.28M470.00K1.63M32.57M24.44M-38.66M54.15M-109.96M-231.82M-27.70M-679.16M
Capital Expenditure -12.30M-22.49M-24.68M-23.68M-24.75M-50.76M-40.91M-51.30M-59.70M-70.75M-63.66M-56.90M-74.05M-78.27M-115.43M-164.68M
Free Cash Flow 58.98M53.92M51.84M69.79M54.42M73.25M106.91M107.75M121.95M101.22M135.13M219.38M104.42M165.22M405.21M588.77M
Share Buybacks 010.02M00------104.67M-144.49M225.56M85.79M300.45M

Ratios (Annual)

Figures in %.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 81.3%79.2%80.5%76.9%76.6%75.7%76.1%76.3%77.6%77.1%72.4%75.0%74.2%65.1%--
Operating Margin % 30.4%29.4%29.7%23.4%29.2%31.6%27.3%25.4%23.7%21.9%14.1%17.9%22.3%8.5%6.6%16.3%
Net Margin % 18.9%18.3%19.1%15.8%19.5%20.7%18.5%16.9%21.9%19.8%13.0%15.6%18.6%7.8%4.1%18.3%
ROE % 23.9%21.5%19.1%14.5%15.8%15.8%12.5%11.1%13.2%11.1%6.8%8.6%10.3%3.1%2.5%11.8%
ROCE % -32.4%28.2%20.4%22.5%22.9%18.2%16.4%14.1%12.1%7.1%9.5%11.9%2.8%3.8%10.0%

Shareholding Pattern

Insiders
0.61%
Institutions
92.36%
Public Float
92.93%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.05% 10.81M $800.56M
2 Jupiter Topco LLC 6.11% 8.20M $607.49M
3 Vanguard Capital Management LLC 3.80% 5.11M $378.37M
4 Vanguard Portfolio Management LLC 3.72% 4.99M $369.98M
5 Invesco Ltd. 3.21% 4.31M $319.27M
6 Kayne Anderson Rudnick Investment Management LLC 3.19% 4.28M $317.04M
7 State Street Corporation 2.77% 3.71M $275.14M
8 Sculptor Capital LP 2.23% 3.00M $222.24M
9 JPMORGAN CHASE & CO 2.04% 2.74M $203.26M
10 Bank of Montreal /CAN/ 1.81% 2.43M $179.68M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GMED

Google News Mon, 07 Sep 2026

Globus Medical, Inc. (GMED) Stock Analysis: Healthcare Innovator with a 31.86% Upside Potential - directorstalkinterviews.com

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxNMk8zZDZNUnpmTnk2cVV2VWg3eEVCanZoRS1wOEpIaHQ3RUNDYVlFb21wTlp6Mm5tNXBHekw5YzBnaXdoTmZXYnNmWGxuVHhUWUdwenR2WFJVcW93SWJZZjB4c0R5MEtnSFFQRm5tclRTR2lQWHA1Z0U2bnNGM2VkVV9vZzRKTkVfdnQ1Tz…

Google News hu, 20 Aug 2026

Globus Medical (GMED) Stock Could Be Undervalued Following Margin Gains Update - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxOT1ViRmtFanRLNGhFcGJ5ZFRZUElCX1NGOWdEYVFGc1dpbEQ3UnlrX0FwdHBFeVJtZ3BqejBoSVpETWVMM1F2Nk5sRTJidTk1b2o1MGlLbUg1ekd2UDRVNTZXbzQ2bEN1NGVRZkh5RUdxd1FIa25HekpzSXg0ZG44cEtjV3hLS0JITnRsTH…

Google News hu, 03 Sep 2026

Globus Medical Slides 3.1% Despite New Product Milestone as Investors Weigh Recent Growth Questions - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxOZmpzNWZqd3kxV1RqR0hOT1NwTDRxd3pEcXUwaWs5Z2ZvMVVIUUhJX1BVYUpWOC1mbW5VWktrXzJpbGprZjQzTEpaZDZyRWhUd1FKV1p6d0NKMmItY2JnWnJOUEFVWm1POWZpN0ZtdDhoNlQzMGpHQXhoLU50MUVVaG9WOGdsN1gxMFU1V1…

Google News hu, 03 Sep 2026

One mobile system combines 3 types of medical imaging. Globus Medical can now sell it in the EU and UK. - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPblMtc0ltcGdvRnA2Z1FBenVwdWo3bVAwYkIzb3NQVjVxdzd4bVo2TXVxSmNLR1J5c0cybi1sRkpyNDUtMl9XNUxfRmRncV9jM1k2dG8yTEV0YmVOWmFnV3h3aC04b01zVWhfRGZmUE42LXBZdkUycUs2cnBkeHkyVEhYNW13WUR6aWxNcU…

Google News Fri, 04 Sep 2026

Globus Medical Inc (GMED) Stock Down 3.1% -- Now Undervalued? GF Score: 94/100 - gurufocus.com

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQTnp0VUJrUkJMVjdFaWZtbUdtNmZxMFJ6cHZqdG5pVUdMc3RDSjV0dm9Ld0F1OFN3cG9wT3dBamhwYmJBdlVsei1obUNxTjZ4OHdSWVhFajlHRllzQ0dsUDNsTE5DWFZVZHRJaWF0WHlpRXl6Mk9wUV92enpiZ2wzdEluaG1GNFhXbEdyTk…

Google News Fri, 08 May 2026

GMED Stock Rises on Q1 Earnings & Revenue Beat, '26 EPS View Raised - May 8, 2026 - Zacks Investment Research

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOQU5BZEkzZHprZ2dFd0tPcHh6eXFtdlBXTlMzQmZuMDFGYTA4M3FZeXM5U05wU2VjdkhTb1ZRSUtSY201R01LMElzdjN2Si1OczJDUExudnNsOHliLXZham8tZzU1eEt3eGZ5bHp5Uk53N1FpMTVqSUVJTHdENTJtcV81elZRVy1MUF9rVk…

GMED — Frequently Asked Questions

What is the current share price of Globus Medical, Inc. (GMED)?

As of 2026-09-19 21:16 PDT, Globus Medical, Inc. (GMED) trades at $75.04 on NYSE. Its 52-week range is $55.10 to $96.82.

What is the market capitalisation of GMED?

Globus Medical, Inc. (GMED) has a market capitalisation of $8.39B on NYSE.

What is the P/E ratio of GMED?

GMED trades at a trailing price-to-earnings (P/E) ratio of 19.19. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.09.

What is the return on equity (ROE) of GMED?

GMED has a return on equity (ROE) of 11.81%. Its return on capital employed (ROCE) is 9.99%.

Is GMED a good stock to buy?

This page provides a data-driven analysis of Globus Medical, Inc. (GMED), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space